Alzheimer's disease may still not be cured. The positive impact of currently approved drugs to existing symptoms is relatively low; they cannot slow down the progression of the disease. In 2006 was published by the American Association for Geriatric Psychiatry, a consensus paper on Alzheimer's treatment.
Acetylcholinesterase inhibitors
The drugs to ensure that AC is broken down more slowly in the brain and therefore present in higher concentrations, thereby reducing the AC-levels by the death of neurons that produce this neurotransmitter to reverse. Representatives of this group are drug galantamine, donepezil and rivastigmine. The effectiveness of the therapy is discussed. The ideal revealed study is that both the patch application, as well as the oral administration of rivastigmine, the cognitive abilities of patients is significantly improved compared with placebo. But there are also studies that show a small effect of acetylcholinesterase inhibitors.
Ibuprofen and other nonsteroidal anti-inflammatory drugs
in retrospective studies it was found in 1995 that rheumatic patients have a significantly reduced risk of developing
Alzheimer's disease, or later the disease broke out among them than with Nichtrheumatikern. It was concluded that this effect is referred to the nonsteroidal anti-inflammatory drugs (NSAIDs) (in English-language publications nonsteroidal anti-inflammatory drugs (NSAIDs) result), taking these patients.
In some transgenic animal models, a reduction of amyloid (Aβ) plaques could be detected in the administration of
ibuprofen.
In humans so far no data are available from randomized double-blind studies that demonstrate a secure mode of action of ibuprofen and other nonsteroidal anti-inflammatory drugs. Because of the significant side effects that are expected for a permanent prophylactic administration of ibuprofen, it is uncontrollable from one administration discouraged. The measures necessary for the possible prevention of
Alzheimer's disease antibodies, doses of nonsteroidal anti-inflammatory drugs are much higher than the normal pain treatment. The nonsteroidal anti-inflammatory drugs induce are suspected cardiovascular problems when they are taken on time and in high doses.
With ibuprofen and derivatives of ibuprofen are currently running for a number of clinical trials in Alzheimer's patients
NMDA receptor antagonist
The influence of the neurotransmitter glutamate, the most common excitatory neurotransmitter in the central nervous system is involved in learning and memory functions, was in Europe in 2002 and in the USA in 2003 approved. The industry's only representative of this drug class is memantine. This is an NMDA receptor (N-methyl-D-aspartate) receptor antagonist and is intended normalize impaired in Alzheimer's dementia glutamatergic signal transmission. Study results show that memantine results in moderate to severe disease after six months to a slight overall improvement in cognitive impairment and impaired activities of daily living.
franzb - 10. Dez, 12:58